Axel Bolte, Chief Executive Officer at Inozyme Pharma, Inc. (INZY), bought 135,500 shares at $3.69 ($500K) on 2022-04-19, disclosed to the SEC on 2022-04-20.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $3.69 | 67,750 | $250K | 50.0% |
| 2 | $3.69 | 67,750 | $250K | 50.0% |
| Total | $3.69 avg | 135,500 | $500K | 100% |
| Filing → |
| OPHT | BUY | 2015-04-01 | $24K | — | Filing → |
| OPHT | BUY | 2013-10-07 | $44K | — | Filing → |
| PTCT | BUY | 2013-06-27 | $300K | — | Filing → |